¼¼°èÀÇ Àü¸³¼± ºñ´ëÁõ(BPH) ±â±â ½ÃÀå(2024-2028³â)
Global Benign Prostatic Hyperplasia (BPH) Devices Market 2024-2028
»óǰÄÚµå : 1581771
¸®¼­Ä¡»ç : TechNavio
¹ßÇàÀÏ : 2024³â 10¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 139 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 2,500 £Ü 3,463,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 4,000 £Ü 5,541,000
PDF (Enterprise License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

Àü¸³¼± ºñ´ëÁõ(BPH) ±â±â ½ÃÀå(2024-2028³â)

Àü¸³¼± ºñ´ëÁõ(BPH) ±â±â ½ÃÀåÀº 2023-2028³â 29¾ï 2,890¸¸ ´Þ·¯·Î ¿¹ÃøµÇ¸ç, ¿¹Ãø ±â°£ µ¿¾È 4.5%ÀÇ CAGR·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. Àü¸³¼± ºñ´ëÁõ(BPH) ±â±â ½ÃÀå¿¡ ´ëÇØ Á¶»ç ºÐ¼®ÇßÀ¸¸ç, ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø, µ¿Çâ, ¼ºÀå ÃËÁø¿äÀÎ, °úÁ¦, ¾à 25°³ º¥´õ¿¡ ´ëÇÑ º¥´õ ºÐ¼® µîÀÇ Á¤º¸¸¦ ÀüÇØµå¸³´Ï´Ù.

ÇöÀç ½ÃÀå ½Ã³ª¸®¿À, Ãֽе¿Çâ ¹× ÃËÁø¿äÀÎ, Àüü ½ÃÀå ȯ°æ¿¡ ´ëÇÑ ÃֽŠºÐ¼®À» Á¦°øÇÕ´Ï´Ù. ½ÃÀåÀº À§Çè ¿äÀÎÀÇ Áõ°¡¿Í ÇÔ²² bphÀÇ À¯º´·ü Áõ°¡, Çõ½ÅÀûÀÎ ±â¼úÀÇ ÃâÇö, ¹æ¼öÆ÷¸¦ ´ëüÇÒ ¼ö ÀÖ´Â È¿°úÀûÀÎ Ä¡·á¹ýÀ¸·Î¼­ ·¹ÀÌÀú Ä¡·á¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡ µîÀÌ ½ÃÀåÀ» ÁÖµµÇϰí ÀÖ½À´Ï´Ù.

½ÃÀå ¹üÀ§
±âÁØ ¿¬µµ 2024
Á¾·á ¿¬µµ 2028
¿¹Ãø ±â°£ 2024-2028
¼ºÀå ¸ð¸àÅÒ °¡¼Ó
Àü³â ´ëºñ 2024³â 4.2%
CAGR 4.5%
ÁõºÐ ±Ý¾× 29¾ï 2,890¸¸ ´Þ·¯

ÀÌ º¸°í¼­´Â ÇâÈÄ ¸î ³â µ¿¾È Àü¸³¼± ºñ´ëÁõ(BPH) ±â±â ½ÃÀåÀÇ ¼ºÀåÀ» ÁÖµµÇÒ ÁÖ¿ä ¿äÀÎ Áß Çϳª·Î »ç¹«½Ç ³» ÃÖ¼Òħ½À ¼ö¼ú¿¡ ´ëÇÑ ¼±È£µµ°¡ ³ô¾ÆÁö´Â °ÍÀ» ²Å¾Ò½À´Ï´Ù. ¶ÇÇÑ, Àü¸³¼± ºñ´ëÁõ¿¡ ´ëÇÑ ·Îº¿ º¸Á¶ ¼ö¼úÀÇ ÀαⰡ ³ô¾ÆÁö°í Àü¸³¼± °Ç°­ ¹× Á¶±â Áø´Ü¿¡ ´ëÇÑ ÀνÄÀÌ ³ô¾ÆÁü¿¡ µû¶ó ½ÃÀå ¼ö¿ä°¡ Å©°Ô Áõ°¡ÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

¸ñÂ÷

Á¦1Àå ÁÖ¿ä ¿ä¾à

Á¦2Àå ½ÃÀå »óȲ

Á¦3Àå ½ÃÀå ±Ô¸ð Æò°¡

Á¦4Àå ½ÃÀå ±Ô¸ð ½ÇÀû

Á¦5Àå Five Forces ºÐ¼®

Á¦6Àå ½ÃÀå ¼¼ºÐÈ­ : Ä¡·áº°

Á¦7Àå °í°´ »óȲ

Á¦8Àå Áö¿ªº° »óȲ

Á¦9Àå ÃËÁø¿äÀÎ, °úÁ¦, ±âȸ, ¾ïÁ¦¿äÀÎ

Á¦10Àå °æÀï »óȲ

Á¦11Àå °æÀï ºÐ¼®

Á¦12Àå ºÎ·Ï

ksm
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Benign Prostatic Hyperplasia (BPH) Devices Market 2024-2028

The benign prostatic hyperplasia (BPH) devices market is forecasted to grow by USD 2928.9 mn during 2023-2028, accelerating at a CAGR of 4.5% during the forecast period. The report on the benign prostatic hyperplasia (BPH) devices market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by increasing prevalence of bph coupled with increasing risk factors, emergence of innovative technologies, and rise in demand for laser therapy as effective alternative to turp.

Market Scope
Base Year2024
End Year2028
Series Year2024-2028
Growth MomentumAccelerate
YOY 20244.2%
CAGR4.5%
Incremental Value$2928.9 mn

Technavio's benign prostatic hyperplasia (BPH) devices market is segmented as below:

By Therapy

By Geographical Landscape

This study identifies the increasing preference for in-office based minimally invasive surgical techniques as one of the prime reasons driving the benign prostatic hyperplasia (BPH) devices market growth during the next few years. Also, growing popularity of robotic-assisted surgery for bph and rising awareness of prostate health and early diagnosis will lead to sizable demand in the market.

The report on the benign prostatic hyperplasia (BPH) devices market covers the following areas:

The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading benign prostatic hyperplasia (BPH) devices market vendors that include Astellas Pharma Inc., biolitec AG, Boston Scientific Corp., Butterfly Medical, Coloplast AS, Convergent Laser Technologies, IPG Photonics Corp., KARL STORZ SE and Co. KG, Medeon Biodesign Inc., Medifocus Inc., Olympus Europa SE and Co. KG, OmniGuide Holdings Inc., ProArc Medical, Richard Wolf GmbH, SRS Medical, Teleflex Inc., Urologix LLC, Vendor Credentialing Service LLC, and Zenflow Inc.. Also, the benign prostatic hyperplasia (BPH) devices market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.

The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive primary and secondary research. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast accurate market growth.

Table of Contents

1 Executive Summary

2 Market Landscape

3 Market Sizing

4 Historic Market Size

5 Five Forces Analysis

6 Market Segmentation by Therapy

7 Customer Landscape

8 Geographic Landscape

9 Drivers, Challenges, and Opportunity/Restraints

10 Competitive Landscape

11 Competitive Analysis

12 Appendix

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â